Is Herceptin effective for targeted treatment of gastric cancer? It has a certain effect

Herceptin has a certain therapeutic effect on HER2-positive gastric cancer patients and some HER2-positive tumor populations. However, due to the inhibitory effect of gastric cancer, the growth of HER2-positive gastric cancer cells is inhibited after taking Herceptin treatment, resulting in the growth of HER2-negative cells, while chemotherapy can inhibit the growth of HER2-negative cells. Therefore, the use of Herceptin is generally carried out simultaneously with chemotherapy to achieve a higher gastric cancer cell control rate.

Gastric cancer is a common disease in life and also a relatively dangerous disease. Suffering from this disease will not only cause stomach discomfort in patients, but may also affect the patient's life. Therefore, when suffering from this disease, it is necessary to treat it in time. Nowadays, many patients in life will use Herceptin for targeted treatment of gastric cancer. So is Herceptin effective for targeted treatment of gastric cancer?
In recent years, with the development of society, many medical devices have also been greatly improved. The rise of molecular targeted therapy now provides new treatment strategies and methods for advanced gastric cancer. According to many medical experts, HER2-positive gastric cancer is a type of disease with specific genetic changes. Currently, trastuzumab combined with chemotherapy is the standard treatment for patients with HER2-positive advanced gastric cancer and is worth recommending. Standardized testing and individualized precision treatment strategies can help patients with advanced gastric cancer prolong their survival.
Gastric cancer patients receive targeted therapy, a molecular-level cancer cell treatment that targets a specific site of the disease known to cause cancer, which may be a protein molecule or a gene fragment within the tumor cell.
Corresponding drug treatments can be designed based on the patient's disease site. When targeted drugs enter the body, they automatically identify the carcinogenic site, bind to it and exert their effects, causing the cancer cells in the tumor to die without affecting the normal tissue cells around the tumor. Therefore, molecular targeted therapy, also known as biological missiles, is a relatively effective method for treating cancer.
HER2 is the abbreviation of human epidermal growth factor receptor-2. It is an important prognostic factor, treatment response predictor and treatment target for gastric cancer treatment, and is also a research hotspot in the field of international cancer biotherapy. If a cancer patient is HER2 positive, it means that the patient has too much HER2 protein on the surface of cancer cells, the cancer cells grow faster and are more invasive, and the condition of such patients is relatively more likely to worsen.
Herceptin can play a certain therapeutic role in treating patients with HER2-positive gastric cancer and some HER2-positive tumor groups. However, due to the inhibitory performance of gastric cancer, after patients take Herceptin, the growth of HER2-positive gastric cancer cells is inhibited, causing the negative cells of this symptom to continue to grow. Chemotherapy can inhibit the growth of HER2-negative cells. Therefore, Herceptin combined with chemotherapy will be more effective in controlling cancer cells.